Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Cutting Edge Systemic Management of Early Stage Breast Cancer: Current and Future Trials Driving Clinical Practice


Description:
The purpose of this activity is to educate pharmacists on new therapeutic agents used for the management of patients with early stage breast cancer.  Mechanism of action, efficacy, and toxicity of pharmacological therapies will be discussed, and current data to support the use of newly approved or novel therapeutic agents for the treatment of patients with early stage breast cancer will be reviewed.
 
Objectives:
1. Analyze current data for neoadjuvant/adjuvant systemic therapy in patients with ESBC.
2. Evaluate the mechanism of action and required monitoring for new pharmacological therapies in
    the management of patients with ESBC.
3. Describe the management of adverse events associated with therapeutic agents for patients with
    ESBC.
 
Activity Number:
0280-0000-16-081-H01-P

This recorded activity is a based on a live program that was offered on October 15, 2016 in Burlington, MA.  
Participants who received credit for the live program should not claim credit for this web based presentation.
 
System Requirements for Participants:
Operating system:  Windows XP, Vista or 7  MAC OS X  Latest Version of Adobe Reader
Browser Internet Explorer 8.0 or above  Google Chrome 16.0 or above  Firefox 7.0 or above  Safari 5.0 or above
 

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Application Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Complete the pre-test
  • Review the content of this activity
  • Successfully complete the post-test with a score of 80% or higher 
  • Complete the activity evaluation
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation is completed.
 
Pharmacists - Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits will NOT be reported.

Support/Credits

Disclosures:
Chad Barnett, PharmD, BCOP; Clinical Pharmacy Specialist - Breast Oncology, Division of Pharmacy, University of Texas MD Anderson Cancer Center Houston, Texas
Presenter has received honorarium as a speaker for ION Solutions
 
The reviewer is Zaven Norigian, PharmD, BCOP; Pharmacy Clinical Specialist, Oncology, Lahey Clinic
Department of Pharmacy, Burlington, Massachusetts
Dr. Norigian is on the speaker’s bureau of Merck and is also on the advisory boards of Amgen, BMS, Eisai, Lilly, Pfizer and Taiho
 
Support for This Activity:
This activity is supported by the Association of Community Cancer Centers (ACCC)
 
American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.
 
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

 

The purpose of this activity is to educate pharmacists on new therapeutic agents used for the management of patients with early stage breast cancer.  Mechanism of action, efficacy, and toxicity of pharmacological therapies will be discussed, and current data to support the use of newly approved or novel therapeutic agents for the treatment of patients with early stage breast cancer will be reviewed. 
 

Objectives

  • Analyze current data for neoadjuvant/adjuvant systemic therapy in patients with ESBC.
  • Evaluate the mechanism of action and required monitoring for new pharmacological therapies in the management of patients with ESBC.
  • Describe the management of adverse events associated with therapeutic agents for patients with ESBC.

Speaker(s)/Author(s)

Chad Barnett, PharmD, BCOP picture

Chad Barnett, PharmD, BCOP
Clinical Pharmacy Specialist, Breast Oncology; Division of Pharmacy University


Brief Bio : Chad M. Barnett, PharmD, BCOP is Clinical Pharmacy Specialist in the Division of Pharmacy at The University of Texas M. D. Anderson Cancer Center in Houston, Texas. In addition to his patient care responsibilities, Dr. Barnett is involved in precepting Oncology Pharmacy Practice Residents on the Breast Medical Oncology Rotation. He has authored numerous book chapters and articles and has presented nationally on topics related to breast cancer and bone health in patients with cancer. Dr. Barnett is also actively involved in breast cancer research. Dr. Barnett received his Doctor of Pharmacy degree from the University of Kansas in Lawrence, Kansas. He completed a Pharmacy Practice Residency at The Methodist Hospital in Houston, Texas and an Oncology Pharmacy Practice Residency at the University of Texas M.D. Anderson Cancer Center in Houston, Texas. Dr. Barnett became a Board Certified Oncology Pharmacist (BCOP) in 2006.

Activity Number

0280-0000-16-081-H01-P

Release Date: Nov 10, 2016
Credit Expiration Date: Nov 10, 2018

CE Hours

1.00

Fee

$0.00